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Steady growth in antiretroviral treatment provision by 
disease management and community treatment programmes
Leigh F Johnson, Heather D McLeod
To the Editor: Although access to highly active antiretroviral 
treatment (HAART) in the South African public health sector 
is closely monitored,1 much remains unknown regarding the 
numbers of HIV-positive individuals receiving HAART outside 
the public health sector. Access to HAART in the private health 
sector is probably considerably better than in the public health 
sector, as private sector patients can often afford the costs of 
HAART, and many are beneficiaries of medical schemes, which 
are required to provide HAART to eligible beneficiaries as a 
prescribed minimum benefit. An investigation conducted in 
2005 found that by the middle of 2005, at least 50 000 South 
Africans were receiving HAART through disease management 
programmes (DMPs), workplace treatment programmes (all 
of which are administered by DMPs) or community treatment 
programmes.2 This investigation was repeated in 2006, with 
the objective of estimating the numbers of people receiving 
HAART by mid-2006 and the rate of growth in numbers on 
treatment between 2005 and 2006.
Method
A list of all DMPs and community treatment programmes 
providing HAART was compiled, in consultation with the 
AIDS Law Project and key informants in the private health 
sector. Seventeen disease management programmes (Aganang, 
Aid for AIDS, Aurum Health, Calibre, CareWorks, Discovery, 
Freeway Direct, Lifesense, Lifeworks, Medicover, Old Mutual, 
Prime Cure, Q.A. Care Plus, Qualsa, Right to Care, Status, Yebo 
Life) and 10 community treatment programmes (managed by 
Right to Care, the South African Catholic Bishops Conference 
and the Treatment Action Campaign) were contacted. 
Results
With the exception of 4 DMPs, all treatment programmes 
provided numbers that could be used to estimate the number 
of patients on HAART by mid-2006. The overall response 
rate was therefore 85% of programmes (76% if only the DMPs 
were considered). Results of the investigation are summarised 
in Table I. The 13 DMPs that responded were treating a 
total of 55 900 patients by mid-2006. The DMP market is 
concentrated, with 46 800 of this total being managed by the 
5 largest programmes. The DMPs that account for the highest 
proportions of this total are Aid for AIDS (36%), Lifesense 
(15%), Discovery Health (11%), Aurum Health (11%) and 
Qualsa (11%). Although these numbers have not been adjusted 
to reflect the 4 DMPs that did not respond, the non-responding 
DMPs are believed to be treating relatively small numbers of 
patients (probably less than 5 000 altogether).
Community treatment programmes were treating 
approximately 11 600 patients with HAART by mid-2006. 
Adding these to the numbers treated by DMPs, the estimated 
total number of individuals receiving HAART through DMPs 
or community treatment programmes by mid-2006 is estimated 
to be at least 67 600.
For those programmes that supplied estimates both in 2005 
and 2006 (10 DMPs and 9 community treatment programmes), 
annualised growth rates in numbers on treatment were 
calculated. When weighted by the estimated number on 
treatment in mid-2005, the average growth rate was 32%. 
The weighted average growth rate was lowest among the 5 
largest DMPs (26%), higher among the smaller DMPs (37%) 
and highest among the community treatment programmes 
(62%). The higher growth rate among community treatment 
programmes is probably due to these programmes having been 
established relatively recently and therefore having to cater to a 
much greater unmet treatment need. 
Discussion
These estimates of numbers on HAART are substantially 
higher than those submitted by medical schemes to the Risk 
Equalisation Fund (REF), which totalled 32 844 in June 2005. 
However, the REF sets out strict conditions under which a 
medical scheme receives reimbursement for someone identified 
with a chronic disease. These REF Verification Criteria require 
not only that a person is identified through ICD-10 coding as 
having that chronic disease but that the person is also shown 
to have been receiving treatment in at least 2 of the previous 
3 months. In a study of the beneficiaries of the four largest 
medical scheme administrators (representing 63.4% of all 
medical scheme beneficiaries in 2005), it was found that the 
number of beneficiaries eligible for HAART in terms of the 
national antiretroviral guidelines3 was substantially greater 
than the number eligible for payment from the REF. Extending 
the REF study figures to the industry as a whole, it is estimated 
that in 2005 there were 59 671 medical scheme beneficiaries 
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identified with HIV in terms of the national antiretroviral 
guidelines, and that 25 680 should have been eligible for 
payments from REF. (The latter figure was estimated using the 
REF Entry and Verification Criteria v2, due to be implemented 
by all administrators from 1 January 2007.) The relatively 
low numbers on HAART that are regularly reported by REF 
therefore appear to be a consequence of the strict requirements 
for reimbursement from the REF, rather than low HAART 
uptake.
The numbers estimated here need to be seen in the light of 
the roughly 181 000 people who had started HAART in the 
public health sector by June 2006, and the trebling in numbers 
cumulatively enrolled on treatment in the public health sector 
between mid-2005 and mid-2006.1 The private and NGO 
sectors contribute significantly to the national effort to expand 
access to HAART, though the higher rates of growth achieved 
in the public health sector imply that the contribution of the 
private and NGO sectors is likely to become increasingly 
small relative to that of the public health sector. No attempt 
has been made to estimate the number of individuals who are 
currently paying for their own treatment and not belonging 
to DMPs, community treatment programmes or public sector 
programmes. These numbers will need to be estimated in 
future, through surveys of general practitioners or studies of 
antiretroviral drug sales, in order to obtain a more complete 
picture of antiretroviral access outside the public health sector.
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Table I. Numbers on antiretroviral treatment and annualised growth rates
     Response   Number   Growth rate
      rate (N)   on HAART*  (weighted average)
   
Five largest DMPs    100% (5)   46 800   26%
Remaining DMPs    67% (12)   9 100†   37%
All DMPs     76% (17)   55 900†   27%
Community treatment programmes  100% (10)   11 600   62%
All treatment programmes   85% (27)   67 600†   32%
* Numbers rounded to the nearest 100, since several programmes did not provide exact estimates.
† Excluding four DMPs for which no estimates were provided.
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